Literature DB >> 6323319

[Ceftizoxime concentration in blood, muscle, and kidney tissue].

M Westenfelder, F Daschner, A Frankenschmidt.   

Abstract

The pharmacokinetic properties of ceftizoxime, a new beta-lactamase-resistant cephalosporin, were investigated in 27 patients following perioperative antimicrobial prophylaxis. 2 g of ceftizoxime were injected before surgery and the concentrations measured in serum, muscle and renal tissue over a period of 30 min to 7 h. The pharmacokinetic data indicated high and long-lasting concentrations of ceftizoxime, especially in the renal tissue; this makes the drug ideal for the treatment of complicated urinary tract infections with obstruction and involvement of the renal tissue, provided the bacteria present are sensitive. The administration of 2 g i. v. every 12 h should be sufficient. In view of the high and long-lasting concentrations, it should be possible to treat uncomplicated urinary tract infections with a single dose of 2 g every 24 h. However, Enterococci, Bacteroides and Pseudomonas aeruginosa are not sufficiently sensitive to ceftizoxime and a combination with an aminoglycoside is thus indicated in the treatment of high-risk patients in the absence of bacteriological tests.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6323319     DOI: 10.1007/bf01641018

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  6 in total

1.  Stomaching: a new concept in bacteriological sample preparation.

Authors:  A N Sharpe; A K Jackson
Journal:  Appl Microbiol       Date:  1972-08

2.  [Clinical studies of the efficacy and tolerance of cefotaxime, ceftizoxime and ceftriaxone in patients with complicated urinary tract infections].

Authors:  M Westenfelder; K Pelz
Journal:  Infection       Date:  1983 Nov-Dec       Impact factor: 3.553

3.  Comparative in vitro study in new cephalosporins.

Authors:  G P Bodey; V Fainstein; A M Hinkle
Journal:  Antimicrob Agents Chemother       Date:  1981-08       Impact factor: 5.191

4.  Antibacterial activity of ceftizoxime, a beta-lactamase-stable cephalosporin.

Authors:  K P Fu; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1980-04       Impact factor: 5.191

5.  Comparative in vitro activity of new beta-lactam antibiotics against anaerobic bacteria.

Authors:  R D Rolfe; S M Finegold
Journal:  Antimicrob Agents Chemother       Date:  1981-11       Impact factor: 5.191

6.  [Pharmacokinetics of ceftizoxim (author's transl)].

Authors:  G Hitzenberger
Journal:  Wien Med Wochenschr       Date:  1981-08-31
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.